Anzeige
Mehr »
Freitag, 05.12.2025 - Börsentäglich über 12.000 News
Einmalige Investmentchancen in den potenziellen Gamechanger der Krebsbehandlung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

NASDAQ Biotech 

WKN:  ISIN:  
Markt oder Branche auswählen:

Aktuelle News zu Aktien im NASDAQ Biotech

  • 24 h
  • 7 Tage
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:  Alle DE EN
LeserMedien
08:30Morgen-Update: Curevac-Aktie stabil - Marktbeobachter rechnen mit Bewegung.
07:06ORIC Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 20251
05:42Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed217WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei...
► Artikel lesen
03:48ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 20251
01:06Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance481Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance...
► Artikel lesen
00:01Vanda jumps as FDA lifts tradipitant partial clinical hold6
DoXenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)3
DoFDA lifts partial clinical hold on Vanda's tradipitant for motion sickness3
DoEntrada Therapeutics, Inc.: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)1
DoWirksamkeit bestätigt: Aktie von Praxis Precision Medicines steigt nach vorzeitigem Studienabbruch sprunghaft an2
DoPraxis Precision Medicines kommt Zulassung für Tremor-Medikament näher1
DoVanda Pharmaceuticals Inc.: FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness10WASHINGTON, Dec. 4, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has lifted the...
► Artikel lesen
DoPraxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies28Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming meeting...
► Artikel lesen
DoMadrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)2
DoPraxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor12BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
► Artikel lesen
Do1 Reason I'll Never Sell Vertex Pharmaceuticals Stock6
DoSolid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst1
DoBioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory9
DoHalozyme granted injunction in Germany barring Merck's subcutaneous Keytruda6
DoHow Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next Chapter13
Weiter >>